CHMP officially recommends Bavarian Nordic's vaccine for monkeypox in Europe

Bavarian Nordic’s vaccine was already approved in the monkeypox indication in the US and Canada – Imvanex is now one step closer to gaining the same authorization in Europe.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by marketwire, translated by daniel pedersen

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted Bavarian Nordic a positive opinion to extend smallpox vaccine Imvanex’s indication to include monkeypox, the firm reported Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading